SIGA Technologies, Inc. (OTCMKTS:SIGA) CFO Daniel J. Luckshire bought 5,000 shares of SIGA Technologies stock in a transaction on Monday, December 9th. The shares were acquired at an average price of $4.34 per share, for a total transaction of $21,700.00.
Shares of SIGA Technologies stock opened at $4.55 on Friday. SIGA Technologies, Inc. has a 1 year low of $4.28 and a 1 year high of $8.09. The business has a 50-day moving average of $5.12 and a two-hundred day moving average of $5.35.
SIGA Technologies (OTCMKTS:SIGA) last released its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.03) EPS for the quarter. The firm had revenue of $8.11 million during the quarter.
Several institutional investors and hedge funds have recently modified their holdings of SIGA. Strs Ohio increased its holdings in SIGA Technologies by 7.2% during the 2nd quarter. Strs Ohio now owns 110,100 shares of the biotechnology company’s stock worth $625,000 after purchasing an additional 7,400 shares in the last quarter. AltraVue Capital LLC boosted its position in shares of SIGA Technologies by 13.4% during the second quarter. AltraVue Capital LLC now owns 2,269,113 shares of the biotechnology company’s stock worth $12,888,000 after buying an additional 268,106 shares during the period. Aperio Group LLC boosted its position in shares of SIGA Technologies by 47.3% during the second quarter. Aperio Group LLC now owns 18,946 shares of the biotechnology company’s stock worth $108,000 after buying an additional 6,088 shares during the period. Janus Henderson Group PLC acquired a new position in shares of SIGA Technologies during the second quarter worth about $219,000. Finally, Stone Ridge Asset Management LLC grew its holdings in shares of SIGA Technologies by 39.2% during the second quarter. Stone Ridge Asset Management LLC now owns 38,404 shares of the biotechnology company’s stock worth $218,000 after buying an additional 10,812 shares in the last quarter. Institutional investors and hedge funds own 6.66% of the company’s stock.
About SIGA Technologies
SIGA Technologies, Inc is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is TPOXX, an orally administered antiviral drug that targets orthopoxviruses infections. TPOXX is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield).
Read More: Neutral Rating
Receive News & Ratings for SIGA Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SIGA Technologies and related companies with MarketBeat.com's FREE daily email newsletter.